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COVID-19 and tuberculosis (TB) are damaging, dual pan-
demics, which are more than mere health crises; they are
socioeconomic and humanitarian crises that require a bio-
social response.1,2
The socioeconomic determinants of TB and COVID-19 are
pernicious and overlapping. Poverty, overcrowded housing
conditions, under- ormalnutrition, chronic comorbidities such
as lung disease and diabetes, and belonging to marginalized,
underserved communities and minority ethnic groups are all
key determinants.3 COVID-19 has distorted health systems at
all levels. It has contracted clinical services, decimated staff-
ing levels, reconfigured laboratories including the repurposing
of GeneXpert modules for TB diagnosis, rolled back hard won
progress toward Universal Health Coverage (UHC) and global
health security,4 and diverted much-needed resources away
from other diseases, including TB.5,6 As a result, the COVID-
19 pandemic is predicted to lead to a 20% increase in TB
deaths in high-burden countries over the next 5 years.7
The health and socioeconomic consequences of TB and
COVID-19 are highly harmful and inequitably distributed.8
Impoverished individuals, households, and communities
continue to be disproportionately affected by both TB and
COVID-19. Social distancing and isolation measures, re-
stricted movement and quarantine, illness, and care-seeking
impose a severe socioeconomic burden, especially on those
who are unemployed, in the informal job sector, or lack ade-
quate social protection.1 These factors are not only associ-
ated with impaired healthcare access and worse health
outcomes9,10; they can push those affected into further im-
poverishment, typifying the “medical poverty trap.”11 The
corrosive influence of COVID-19 and its related mitigation
strategies onmental health anddomestic violence is aparallel,
concomitant emergency.12
Far from being great “levellers,” these intersecting pan-
demics have reemphasized intolerable and persistent global
inequalities in health, wealth, and well-being—inequalities
that are aggravated by poverty of voice, agency, and oppor-
tunity.13 However, the convergent challenges brought about
by COVID-19 and TB enable us to identify potential opportu-
nities to mitigate their impact.
Key to this is collaboration toward achieving the interlaced
WHO Sustainable Development Goals (SDGs)—specifically
SDG1 (No poverty), SDG2 (Zero hunger), SDG3 (Good health
and well-being), SDG8 (Decent work and economic growth),
and SDG10 (Reducing inequalities).14 Modeling studies have
suggested that eradicating poverty and providing social pro-
tection would reduce TB incidence by more than 84% by
203515 – similar modeling studies would be of benefit when
applied to COVID-19. Moreover, in theWHO End TB Strategy—
for the first time in the modern era of TB control—we were
provided with an ambitious socioeconomic goal that “zero
TB-affected families face catastrophic costs” by 2025.16
In reality, catastrophic costs mitigation should be a global
goal regardless for all states of ill health, whether mental or
physical, noncommunicable or communicable, occupational or
accidental, COVID-19 or TB.
The article by Fuady et al.17 in this issue of the American
Journal of Tropical Medicine and Hygiene examining the im-
pact of COVID-19 on costs incurred by people with TB and
their households is topical, timely, and moves this field for-
ward. The article draws attention to this overlooked area of
research, policy, and practice, and provides an informative
conceptual framework that will help us to develop better bio-
social responses to combat both TB and COVID-19.
So, how can we address the socioeconomic determinants
andconsequencesof TBandCOVID-19, andpreventwhat our
colleagues have rightly called the “perfect storm?”18
First, there is an urgent need to better understand the so-
cioeconomic impacts of COVID-19, especially in the most
vulnerable groups. Evidence from nationally representative
surveys of costs incurred by people with TB and their
households (known as “TB Patient Cost Surveys”) shows that
more than one in two TB-affected households worldwide
incur catastrophic costs.19 These surveys and related
mixed-methods research also show that significant drivers of
catastrophic costs are: lost income and time, reduced pro-
ductivity, and significant non-medical expenses such as travel
to access healthcare services and nutritional expenditure
meet even basic food requirements.20–22 In certain regions,
these costs may be exacerbated by an unregulated and
convoluted public–private sector mix23 and avoidable ex-
penditure on unproven, costly “therapies” including nutritional
supplements. Furthermore, mask-wearing and respiratory
symptoms of COVID-19 and TB may be associated with di-
agnostic uncertainty, stigma, discrimination, and isolation,
which further compound challenges to accessing care and
appropriate treatment.18,24 We have the perfect opportunity
now to measure and evaluate the socioeconomic impacts
along the care-seeking pathway for people with acute,
chronic, or acute-on-chronic respiratory symptoms.
Second, understanding the patient pathway will provide
valuable information to inform assessment of the progress
made toward the SDGs. This is particularly pertinent with
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relation to achieving SDG3 and UHC but also to the under-
acknowledged yet acute need to expand social protection
coverage and establish basic universal social protection
floors.25,26 National lockdown, “stay at home,” and “shelter in
place” policies have already had a detrimental effect on indi-
vidual and household incomes and been associated with
contractions in national gross domestic product indices.14
There is a clear negative association between incidence and
mortality of TB and proportional governmental expenditure on
social protection.27,28 It is as yet unclear whether the same
association exists with relation to COVID-19, but that evi-
dence will be vital to shape our response.
Third, despite their detrimental effects, large-scale non-
pharmacological interventions may also provide a useful
opportunity to explore ways in which we can mitigate care-
seeking costs of TB, COVID-19, and other poverty-related
diseases. For example, measures that reduce the need for
daily encounters between TB patients and healthcare staff to
reduce COVID-19 transmission have been rapidly rolled out
and could be further strengthened.29 One suchmeasure is the
WHO recommendation of all-oral TB treatment regimens for
multidrug- and rifampicin-resistant TB and extensively drug-
resistant TB.30 This strategy can lower costs for people with
TB and their households through reduction of direct costs
associatedwith traveling to health facilities for daily injections,
and/or opportunity costs associatedwith lost productivity and
income due to hospitalization during the initial “intensive”
phase of treatment.31 Similarly, intensified use of digital health
technologies, such as video observed therapy and electronic
medication monitors to support programs and affected peo-
ple could pave the way to models of care that may lower
medical, non-medical, and opportunity costs even further.32
Fourth, the COVID-19 pandemic has brought into sharp
relief theweaknessesof health systems that are imbalanced—
in terms of both funding and focus—toward secondary care.
We could use this opportunity to garner feedback from users
of the health system on how best to improve the care we
provide not only in secondary care but at all levels.33 This is
also an opportune moment to reconsider how best to engage
communities and community health workers to harness their
commitment, knowledge, trust, and understanding of their
local areas.34 Outreach involving peer support and advocacy
is amuch needed vehicle of change to not only reduce care-
seeking costs by bringing care to people’s door in the
community but also to use peer-led education and in-
formation as a tool to promote agency, to empower, and to
combat stigma.35 In this way, we could ensure no one is left
behind and eradicate the misplaced blame attributed to the
so-called “hard-to-reach” groups who, in reality, are un-
derserved by static and fragmented local health and social
care systems.36
Finally, building on the aforementioned, this is the time to
move away from vertical public health programs. We need
health systems that are responsive to the needs of vulnerable
communities and resilient to the threat of infections, especially
those which are airborne. A major step toward reaching this
goal would be inclusive horizontal approaches that integrate
biomedical strategies to prevent and tackle the health impacts
of syndemics with biosocial strategies to address their de-
terminants and consequences.37 People affected by poverty-
related illnesses, including respiratory illnesses, would benefit
vastly from this joined-up approach.
The COVID-19 pandemic is threatening decades of prog-
ress made in TB control and, undoubtedly, continues to have
the biggest impact on people and communities affected by TB
and poverty. Predicted increases in levels of food insecurity,
rising impoverishment, and contraction of gross domestic
product have led to cross-sectoral bodies, including theWHO,
academia, and civil society, to ring the alarm bell.38 Findings
from ongoing and future TB Patient Cost Surveys will provide
an accurate estimate of the socioeconomic impact of COVID-
19 on people with TB and their households. The surveys will
simultaneously provide critical data to inform broader map-
ping of social determinants and consequences of ill health,
uptake and coverage of social protection strategies and UHC,
and therefore progress toward the SDGs.
As we begin what we hope will be a brighter 2021, we must
turn the challenges of the COVID-19 and TB pandemics into
an opportunity to refine biosocial strategies that not only im-
prove health and well-being but also address poverty and
inequality.
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